349 related articles for article (PubMed ID: 17869669)
1. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
Hicks KO; Myint H; Patterson AV; Pruijn FB; Siim BG; Patel K; Wilson WR
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):560-71. PubMed ID: 17869669
[TBL] [Abstract][Full Text] [Related]
2. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
3. A combined pharmacokinetic model for the hypoxia-targeted prodrug PR-104A in humans, dogs, rats and mice predicts species differences in clearance and toxicity.
Patel K; Choy SS; Hicks KO; Melink TJ; Holford NH; Wilson WR
Cancer Chemother Pharmacol; 2011 May; 67(5):1145-55. PubMed ID: 20683596
[TBL] [Abstract][Full Text] [Related]
4. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia.
Guise CP; Wang AT; Theil A; Bridewell DJ; Wilson WR; Patterson AV
Biochem Pharmacol; 2007 Sep; 74(6):810-20. PubMed ID: 17645874
[TBL] [Abstract][Full Text] [Related]
5. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures.
Hicks KO; Pruijn FB; Sturman JR; Denny WA; Wilson WR
Cancer Res; 2003 Sep; 63(18):5970-7. PubMed ID: 14522924
[TBL] [Abstract][Full Text] [Related]
6. The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
Guise CP; Abbattista MR; Singleton RS; Holford SD; Connolly J; Dachs GU; Fox SB; Pollock R; Harvey J; Guilford P; Doñate F; Wilson WR; Patterson AV
Cancer Res; 2010 Feb; 70(4):1573-84. PubMed ID: 20145130
[TBL] [Abstract][Full Text] [Related]
7. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
Wilson WR; Hicks KO; Pullen SM; Ferry DM; Helsby NA; Patterson AV
Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
[TBL] [Abstract][Full Text] [Related]
8. Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice.
Gu Y; Guise CP; Patel K; Abbattista MR; Li J; Sun X; Atwell GJ; Boyd M; Patterson AV; Wilson WR
Cancer Chemother Pharmacol; 2011 Mar; 67(3):543-55. PubMed ID: 20473609
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104.
Patterson AV; Ferry DM; Edmunds SJ; Gu Y; Singleton RS; Patel K; Pullen SM; Hicks KO; Syddall SP; Atwell GJ; Yang S; Denny WA; Wilson WR
Clin Cancer Res; 2007 Jul; 13(13):3922-32. PubMed ID: 17606726
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-selective 3-alkyl 1,2,4-benzotriazine 1,4-dioxides: the influence of hydrogen bond donors on extravascular transport and antitumor activity.
Hay MP; Pchalek K; Pruijn FB; Hicks KO; Siim BG; Anderson RF; Shinde SS; Phillips V; Denny WA; Wilson WR
J Med Chem; 2007 Dec; 50(26):6654-64. PubMed ID: 18052317
[TBL] [Abstract][Full Text] [Related]
11. Extravascular transport of drugs in tumor tissue: effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures.
Pruijn FB; Sturman JR; Liyanage HD; Hicks KO; Hay MP; Wilson WR
J Med Chem; 2005 Feb; 48(4):1079-87. PubMed ID: 15715475
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
[TBL] [Abstract][Full Text] [Related]
13. Metabolism and excretion of the novel bioreductive prodrug PR-104 in mice, rats, dogs, and humans.
Gu Y; Atwell GJ; Wilson WR
Drug Metab Dispos; 2010 Mar; 38(3):498-508. PubMed ID: 20019245
[TBL] [Abstract][Full Text] [Related]
14. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
Hicks KO; Pruijn FB; Secomb TW; Hay MP; Hsu R; Brown JM; Denny WA; Dewhirst MW; Wilson WR
J Natl Cancer Inst; 2006 Aug; 98(16):1118-28. PubMed ID: 16912264
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: the role of extravascular transport.
Hay MP; Hicks KO; Pruijn FB; Pchalek K; Siim BG; Wilson WR; Denny WA
J Med Chem; 2007 Dec; 50(25):6392-404. PubMed ID: 18001018
[TBL] [Abstract][Full Text] [Related]
16. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
Foehrenbacher A; Patel K; Abbattista MR; Guise CP; Secomb TW; Wilson WR; Hicks KO
Front Oncol; 2013; 3():263. PubMed ID: 24109591
[TBL] [Abstract][Full Text] [Related]
17. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
Kyle AH; Minchinton AI
Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation of anticancer prodrug PR-104A: species differences, identification of human UDP-glucuronosyltransferases, and implications for therapy.
Gu Y; Tingle MD; Wilson WR
J Pharmacol Exp Ther; 2011 Jun; 337(3):692-702. PubMed ID: 21427202
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
20. Diflavin oxidoreductases activate the bioreductive prodrug PR-104A under hypoxia.
Guise CP; Abbattista MR; Tipparaju SR; Lambie NK; Su J; Li D; Wilson WR; Dachs GU; Patterson AV
Mol Pharmacol; 2012 Jan; 81(1):31-40. PubMed ID: 21984255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
